← Leaderboards
Christopher S. Coffey
Palladian Partners, Inc.
$44,293,283
Attributed
$68,197,245
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.8M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$68,197,245 · 9
By mechanism
U01$38,006,158 · 3
U24$11,030,472 · 1
R18$8,752,370 · 1
U44$5,635,109 · 1
R01$2,425,615 · 1
R25$2,282,242 · 1
Top collaborators
- Merit E Cudkowicz9 shared
- Laura A Frey Law9 shared
- Kathleen A Sluka9 shared
- Michael J Brownstein5 shared
- Laurie Gutmann5 shared
- Steven M Hersch5 shared
- Roger J Lewis5 shared
- William Joseph Meurer5 shared
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsProtocols DocumentationRandomizedMonitorSuccessData ManagementDesignResearch PersonnelLeadershipUniversitiesResearch DesignFutureNational Institute Of Neurological Disorders And StrokeBaseFundingReportingClinical Trials Data Monitoring CommitteesPositioning AttributeUnited States National Institutes Of HealthProceduresCommunicationEnrollmentInnovationCollaborations
Grant awards (52)
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) DCC$1,945,324
U01 · FY2025 · NS · contact PI
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) DCC$1,886,965
U01 · FY2024 · NS · contact PI
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) DCC$1,959,665
U01 · FY2023 · NS · contact PI
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program$2,533,120
U24 · FY2022 · NS
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) - DCC$1,763,568
U01 · FY2022 · NS · contact PI
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program$503,908
U24 · FY2022 · NS
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program$376,914
U24 · FY2022 · NS
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program$77,250
U24 · FY2022 · NS
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program$2,515,231
U24 · FY2021 · NS
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) - DCC$1,763,568
U01 · FY2021 · NS · contact PI
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program$1,417,940
U24 · FY2021 · NS
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program: Administrative Supplement$77,250
U24 · FY2021 · NS
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program$2,515,744
U24 · FY2020 · NS
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) - DCC$1,763,568
U01 · FY2020 · NS · contact PI
Topiramate as a Disease Altering Therapy for CSPN$874,009
U01 · FY2020 · NS
Topiramate as a Disease Altering Therapy for CSPN$1,847,422
U01 · FY2019 · NS
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) - DCC$1,763,568
U01 · FY2019 · NS · contact PI
Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program$1,013,115
U24 · FY2019 · NS
Topiramate as a Disease Altering Therapy for CSPN$2,219,043
U01 · FY2018 · NS
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) - DCC$1,795,894
U01 · FY2018 · NS · contact PI
Tolerability of SRX246 in Huntington's Disease Patients$764,163
U44 · FY2018 · NS
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention$483,925
R18 · FY2018 · HL
Enhancing Scientific Inquiry in Clinical Neurosciences Through Methodology Traini$466,189
R25 · FY2018 · NS
Topiramate as a Disease Altering Therapy for CSPN$2,399,189
U01 · FY2017 · NS
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention$1,894,144
R18 · FY2017 · HL
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC$1,514,273
U01 · FY2017 · NS · contact PI
Tolerability of SRX246 in Huntington's Disease Patients$1,480,173
U44 · FY2017 · NS
Enhancing Scientific Inquiry in Clinical Neurosciences Through Methodology Traini$466,189
R25 · FY2017 · NS
Tolerability of SRX246 in Huntington's Disease Patients$61,234
U44 · FY2017 · NS
Tolerability of SRX246 in Huntington's Disease Patients$2,214,354
U44 · FY2016 · NS
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention$2,056,749
R18 · FY2016 · HL
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC$1,561,366
U01 · FY2016 · NS · contact PI
Enhancing Scientific Inquiry in Clinical Neurosciences Through Methodology Traini$466,189
R25 · FY2016 · NS
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention$2,130,152
R18 · FY2015 · HL
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC$1,601,880
U01 · FY2015 · NS · contact PI
Tolerability of SRX246 in Huntington's Disease Patients$1,115,185
U44 · FY2015 · NS
Enhancing Scientific Inquiry in Clinical Neurosciences Through Methodology Traini$466,189
R25 · FY2015 · NS
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention$2,187,400
R18 · FY2014 · HL
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC$1,605,564
U01 · FY2014 · NS · contact PI
Amitriptyline and Topiramate in the Prevention of Childhood Migraine: DCC$1,162,024
U01 · FY2014 · NS · contact PI
Enhancing Scientific Inquiry in Clinical Neurosciences Through Methodology Traini$417,486
R25 · FY2014 · NS
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC$1,665,128
U01 · FY2013 · NS · contact PI
Amitriptyline and Topiramate in the Prevention of Childhood Migraine: DCC$1,088,648
U01 · FY2013 · NS · contact PI
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC$1,725,284
U01 · FY2012 · NS · contact PI
Amitriptyline and Topiramate in the Prevention of Childhood Migraine: DCC$1,154,967
U01 · FY2012 · NS · contact PI
A collaborative model to improve BP control and minimize racial disparities--DCC$815,462
R01 · FY2012 · HL · contact PI
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC$34,875
U01 · FY2012 · NS · contact PI
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCC$1,776,295
U01 · FY2011 · NS · contact PI
Amitriptyline and Topiramate in the Prevention of Childhood Migraine: DCC$1,134,071
U01 · FY2011 · NS · contact PI
A collaborative model to improve BP control and minimize racial disparities--DCC$818,108
R01 · FY2011 · HL · contact PI
A collaborative model to improve BP control and minimize racial disparities--DCC$792,045
R01 · FY2010 · HL · contact PI
Scientific Advances in Adaptive Clinical Trial Design$65,279
R13 · FY2009 · NS